Provided by Tiger Trade Technology Pte. Ltd.

Immunic, Inc.

10.37
-0.8600-7.66%
Pre-market: 10.670.3000+2.89%09:13 EDT
Volume:287.83K
Turnover:3.05M
Market Cap:141.03M
PE:-2.59
High:11.27
Open:11.19
Low:10.30
Close:11.23
52wk High:17.43
52wk Low:5.06
Shares:13.60M
Float Shares:11.92M
Volume Ratio:0.88
T/O Rate:2.42%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.9979
EPS(LYR):-6.2414
ROE:-138.17%
ROA:-66.80%
PB:1.11
PE(LYR):-1.66

Loading ...

Immunic reports Q2 EPS (80c), consensus ($1.16)

TIPRANKS
·
Aug 11

Immunic Q2 Net Loss Widens to $34.1 Million; Operating Expenses Rise to $35.3 Million

Reuters
·
Aug 11

Immunic Files Form 3 for Director Elena Ridloff, Reporting no Beneficial Ownership

Reuters
·
Aug 11

Top News Today/Canada: Barrick Settles Newmont Dispute, Clearing Way to List Its Gold Assets

Dow Jones
·
Aug 11

Immunic Appoints Elena Ridloff to Board of Directors

Reuters
·
Aug 11

Immunic Inc Expected to Post a Loss of $1.19 a Share - Earnings Preview

Reuters
·
Aug 03

Immunic Updates Corporate Strategy, Highlights Vidofludimus Plans

TIPRANKS
·
Jul 15

Immunic Publishes Investor Presentation Outlining Vidofludimus Calcium Phase 3 Program in Multiple Sclerosis

Reuters
·
Jul 14

Immunic Names CEO Erik Lundgren to Board After Tamar Howson Retirement Resignation

Reuters
·
Jul 07

Immunic Holds Annual Shareholder Meeting, Backs 6 Million-share Increase to Equity Plan

Reuters
·
Jun 30

Immunic joins H.C. Wainwright Neuro Perspectives Expert Summit fireside chat

Reuters
·
Jun 10

Immunic files Form 3 initial beneficial ownership statement for CEO Erik Lundgren

Reuters
·
Jun 02

Immunic publishes investor presentation on oral immunology pipeline led by vidofludimus calcium in multiple sclerosis

Reuters
·
Jun 01

Stifel Nicolaus Reaffirms Their Buy Rating on Immunic (IMUX)

TIPRANKS
·
May 29

Immunic presents new Phase 2 CALLIPER analyses of vidofludimus calcium in progressive multiple sclerosis at CMSC 2026

Reuters
·
May 28

Eqs-News: Immunic to Present Additional Phase 2 Calliper Trial Data for Vidofludimus Calcium at the Cmsc Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis

THOMSON REUTERS
·
May 28

Immunic Appoints New CEO to Lead MS Strategy

TIPRANKS
·
May 27

Immunic names ex-Genentech executive Erik Lundgren CEO, replacing Daniel Vitt

Reuters
·
May 27

Immunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer

THOMSON REUTERS
·
May 27

Immunic Is Maintained at Buy by B. Riley Securities

Dow Jones
·
May 22